A PHASE 2 TRIAL OF AN ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONIST IN SCHIZOPHRENIA

被引：0
|
作者：
Freedman, Robert [1 ]
Olincy, A. [1 ]
Johnson, L. [1 ]
Buchanan, R. W. [2 ]
Kem, W. R. [3 ]
机构：
[1] Univ Colorado, Aurora, CO USA
[2] Maryland Psychiat Res Ctr, Baltimore, MD 21228 USA
[3] Univ Florida, Gainesville, FL USA
来源：
SCHIZOPHRENIA BULLETIN | 2009年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：335 / 335
页数：1
相关论文
共 50 条
  • [1] Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia
    Walling, David
    Marder, Stephen R.
    Kane, John
    Fleischhacker, W. Wolfgang
    Keefe, Richard S. E.
    Hosford, David A.
    Dvergsten, Chris
    Segreti, Anthony C.
    Beaver, Jessica S.
    Toler, Steven M.
    Jett, John E.
    Dunbar, Geoffrey C.
    [J]. SCHIZOPHRENIA BULLETIN, 2016, 42 (02) : 335 - 343
  • [2] Schizophrenia and the α7 nicotinic acetylcholine receptor
    Martin, Laura F.
    Freedman, Robert
    [J]. INTEGRATING THE NEUROBIOLOGY OF SCHIZOPHRENIA, 2007, 78 : 225 - 246
  • [3] Phase 2 clinical trial of TC-5619, an alpha 7 nicotinic receptor agonist in the treatment of negative and cognitive symptoms in schizophrenia
    Hosford, D.
    Dvergsten, C.
    Beaver, J.
    Segreti, A. C.
    Toler, S.
    Farr, M. G.
    Joseph, M.
    Jett, J.
    Lippiello, P.
    Bencherif, M.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S531 - S532
  • [4] Initial phase 2 trial of a nicotinic agonist in schizophrenia
    Olincy, Ann
    Freedman, Robert
    Buchanan, Robert W.
    Harris, Josette G.
    Gold, James M.
    Johnson, Lynn L.
    Zerbe, Gary O.
    Soti, Ferenc
    Kem, William R.
    [J]. BIOLOGICAL PSYCHIATRY, 2008, 63 (07) : 124S - 124S
  • [5] Initial phase 2 trial of a nicotinic agonist in schizophrenia
    Freedman, Robert
    Olincy, Ann
    Buchanan, Robert W.
    Harris, Josette G.
    Gold, James M.
    Johnson, Lynn
    Allensworth, Diana
    Guzman-Bonilla, Alejandrina
    Clement, Bettye
    Ball, M. Patricia
    Kutnick, Jay
    Pender, Vicki
    Martin, Laura F.
    Stevens, Karen E.
    Wagner, Brandie D.
    Zerbe, Gary O.
    Soti, Ferenc
    Kem, William R.
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2008, 165 (08): : 1040 - 1047
  • [6] Pilot study of an α7 nicotinic acetylcholine receptor agonist adjuvant therapeutic strategy for schizophrenia
    Deutsch, Stephen I.
    Schwartz, Barbara L.
    Schooler, Nina R.
    Rosse, Richard B.
    Mastropaolo, John
    Gaskins, Brooke L.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S250 - S250
  • [7] Alpha7 nicotinic acetylcholine receptor agonist improves survival during endotoxemia
    Chen, F.
    Cai, B.
    Dong, W.
    Deitch, E. A.
    Ulloa, L.
    [J]. SHOCK, 2008, 29 : 80 - 80
  • [8] The combination of CDP-choline and galantamine as a clinical alpha-7 nicotinic acetylcholine receptor (nAChR) agonist intervention in schizophrenia
    Deutsch, S. I.
    Schooler, N.
    Schwartz, B. L.
    Rosse, R. B.
    Mastropaolo, J.
    Gaskins, B. L.
    [J]. SCHIZOPHRENIA BULLETIN, 2007, 33 (02) : 427 - 427
  • [9] Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia
    Young, Jared W.
    Geyer, Mark A.
    [J]. BIOCHEMICAL PHARMACOLOGY, 2013, 86 (08) : 1122 - 1132
  • [10] A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia
    Jeffrey A Lieberman
    Geoffrey Dunbar
    Anthony C Segreti
    Ragy R Girgis
    Frances Seoane
    Jessica S Beaver
    Naihua Duan
    David A Hosford
    [J]. Neuropsychopharmacology, 2013, 38 : 968 - 975
12345